SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Immunomedics (IMMU) - moderated
An SI Board Since September 2006
Posts SubjectMarks Bans Symbol
63365 356 15 IMMU
Emcee:  idahoranch1 Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
62736>> Biogen's P4 was not generating additional data. It's sole purpoweatherproof-8/2/2024
62735Perfect, Stew! I vote for that outcome. :o)weatherproof-8/2/2024
62734Scorman, it would be full approval, not AA.ghettogoulash-8/2/2024
62733Biogen's P4 was not generating additional data. It's sole purpose was toghettogoulash-8/2/2024
62732On SAVA, let me make it simple in a few words: Nov first phase 3 shows x% of patscorman128/1/2024
62731Yes, that was one of the studies generating additional data post AA. They also weatherproof-8/1/2024
62730Take Biogen's P4 for Aduhelm as an example: "The study, as previously ghettogoulash-8/1/2024
62729Missling said that? Doesn't surprise me.ghettogoulash-8/1/2024
62728That's sort of where I started the thread a few days ago. I mentioned that weatherproof-8/1/2024
62727My bad. But the same applies. A confirmatory trial would have to be a standard Rghettogoulash-8/1/2024
62726I didn't say for AA. I said as a post-marketing confirmatory trial should Aweatherproof-8/1/2024
62725Almost zero chance OLE data would be considered by the FDA for AA. Not only is ighettogoulash-8/1/2024
62724Thanks, yes, SAVA.weatherproof-8/1/2024
62723Here is the salient point in the aforementioned FDA guidance on AVXL's explaweatherproof18/1/2024
62722When you say CASA you really mean SAVA right? Also, I invited Matt Nachtrab to plhky346528/1/2024
62721My query goes to something that I feel is being missed by the responses here. Lweatherproof28/1/2024
62720P3 OLE will not be a factor in drug approval. The only point about the company sghettogoulash18/1/2024
62719That is a great question. Unfortunately, I believe the company is a one-trick pojhcimmu-7/31/2024
62718Sorry, I don't know Nachtrab. I was just wondering if by CASA expanding theweatherproof17/31/2024
62717I like the way you re-positioned the question. Do you think if the unblinded datjhcimmu-7/31/2024
62716Allow me to ask the question in a different manner. With no FDA guidance or somweatherproof-7/31/2024
62715My understanding is not that SAVA is drawing a target around a landed arrow, butjhcimmu-7/31/2024
62714Thanks for taking the time to regurgitate the statistical perspective. Forgive weatherproof17/31/2024
62713[graphic]ghettogoulash17/31/2024
62712IMNN: Phase 2 data for ovarian cancer is crazy good. Specifically, Overall Survighettogoulash-7/31/2024
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News